WOODCLIFF LAKE, N.J. (AP) — Generic drug developer Par Pharmaceutical Companies Inc. said Monday a federal court in Delaware ruled in the company’s favor in a patent dispute over the pain drug Ultram ER. The company wants to sell generic versions of the extended-release drug, which is also known as tramadol. Purdue Pharma LP is the patent holder, while Biovail Corp. and a division of Johnson & Johnson collaborate in selling the drug. Par said it has tentative approval from the U.S. Food and Drug Administration for the 100mg and 200mg strength versions of tramadol ER. In a separate statement, Canadian drug developer Biovail said the decision could affect its revenue if Par decides to launch generic versions of Ultram ER. Biovail said it recorded $81.9 million in revenue from Ultram ER in 2008.
Related Articles Read More >

Navigating the new regulatory terrain pharma companies face with IRA and 340B

FDA warns against compounded oral ketamine for psychiatric disorders

FDA resolves drug shortage for Novartis’ prostate cancer drug Pluvicto
